Do patients and doctors really understand this parathyroid drug?
NCT ID NCT05556629
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study checked how well patients and doctors understand the risks and safe use of NATPARA, a drug for hypoparathyroidism. About 200 people took a survey online, by phone, or on paper. No medicine was given—the goal was just to measure knowledge and attitudes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shire-NPS Pharmaceuticals, INC. (Shire now part of Takeda)
Lexington, Massachusetts, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a daily shot free teens from calcium pills?
- Weekly shot could free hypoparathyroidism patients from daily pills
- New daily shot could ease rare hormone disorder
- Glowing goggles could prevent calcium crash after thyroid surgery
- MRNA therapy offers hope for rare hormone disorder
- MRNA therapy takes on rare hormone disorder